Cutaneous squamous cell carcinoma and related entities: Epidemiology, clinical and histological features, and basic science overview

Prieto-Granada, Carlos; Rodriguez‐Waitkus, Paul

doi:10.1016/j.currproblcancer.2015.07.005

Cited by 30 publications

(16 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The occurrence of cutaneous squamous cell carcinoma (CSCC), one of the most common non-melanoma skin cancers, is increasing mainly due to the damage of the ozonosphere and the lack of risk awareness (1,2). Certain factors, including infection, chemical substances, inheritance and immune responses, have been implicated in the development and progression of CSCC (3). High rates of recurrence and metastasis contribute to the poor prognosis of patients with CSCC (4).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‑186 promotes cell proliferation and inhibits cell apoptosis in cutaneous squamous cell carcinoma by targeting RETREG1

Liu

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

MicroRNAs (miRs), a class of small non-coding RNAs, have been demonstrated to be involved in the development and progression of human malignancies, including cutaneous squamous cell carcinoma (CSCC). miR-186 serves a suppressive role in certain common types of human cancer; however, its exact function in CSCC has not been reported previously. In the present study, the expression of miR-186 was significantly increased in CSCC tissues compared with adjacent non-tumour tissues. Overexpression of miR-186 significantly promoted CSCC cell proliferation while inhibiting cell apoptosis. Reticulophagy regulator 1 (RETREG1), a gene that is significantly downregulated in CSCC tissues and cell lines, was identified as a novel target of miR-186. In addition, the expression of RETREG1 was inversely correlated with miR-186 expression in CSCC tissues. Furthermore, the expression of RETREG1 was negatively regulated by miR-186 in CSCC cells, and restoration of RETREG1 attenuated the effects of miR-186 on CSCC cells. Taken together, the results of the current study suggest that miR-186 serves an oncogenic role in CSCC and may be used as a potential therapeutic target for the treatment of this disease.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA‑186 promotes cell proliferation and inhibits cell apoptosis in cutaneous squamous cell carcinoma by targeting RETREG1

Liu

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Cutaneous squamous cell carcinoma (SCC) is a malignant neoplasm of epidermal keratinocytes. It is the second most frequent nonmelanoma skin cancer (NMSC) and one of the most common malignancies in the world . With an increasing incidence worldwide, cutaneous SCC predominantly affects light‐skinned individuals .…”

Section: Introductionmentioning

confidence: 99%

Review of high‐risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology

et al. 2016

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (SCC) is a malignancy that arises from epidermal keratinocytes. Although the majority of cutaneous SCC cases are easily treated without further complication, some behave more aggressively and carry a poor prognosis. These "high-risk" cutaneous SCCs commonly originate in the head and neck and have an increased tendency toward recurrence, local invasion, and distant metastasis. Factors for high-risk cutaneous SCC include large size (>2 cm), a deeply invasive lesion (>2 mm), incomplete excision, high-grade/desmoplastic lesions, perineural invasion (PNI), lymphovascular invasion, immunosuppression, and high-risk anatomic locations. Both the National Comprehensive Cancer Network (NCCN ) and the American Joint Committee on Cancer (AJCC) identify several of these high-risk features of cutaneous SCC. The purpose of this article was to review the high-risk features included in these guidelines, as well as their notable discrepancies and omissions. We also provide a brief overview of current prophylactic measures, surgical options, and adjuvant therapies for high-risk cutaneous SCC. © 2016 Wiley Periodicals, Inc. Head Neck 39: 578-594, 2017.

show abstract

“…This suggested that false‐negative results may be caused by complex changes to the lymphatic flow because of chronic inflammation and scarring. However, because cSCC is associated with chronic inflammation and scarring, it may not be possible to omit the risk of false‐negatives for SLNB in cSCC. Furthermore, a negative SLN was not associated with a good prognosis, resulting in a low sensitivity for SLNB in cSCC …”

Section: Discussionmentioning

confidence: 99%

“…After basal cell carcinoma, cutaneous squamous cell carcinoma (cSCC) is the second most common cutaneous cancer, worldwide, especially in the elderly . Basal cell carcinoma rarely causes metastases, whereas invasive cSCC has a 3–5% metastasis rate …”

Section: Introductionmentioning

confidence: 99%

Availability of sentinel lymph node biopsy for cutaneous squamous cell carcinoma

Maruyama

Tanaka

Fujisawa

et al. 2016

The Journal of Dermatology

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma is the second common cutaneous cancer, especially in the elderly. Sentinel lymph node biopsy is generally performed in breast cancers and cutaneous melanomas to detect occult nodal metastases. The benefit of sentinel lymph node biopsy in improving cutaneous squamous cell carcinoma prognosis is doubtful. One hundred and sixty-nine patients who underwent treatment for cutaneous squamous cell carcinoma between 2004 and 2015, and who were followed up for at least 6 months or developed metastases within the follow-up period were included. Forty-nine patients underwent sentinel lymph node biopsy, whereas 120 patients did not, including 13 who exhibited clinical lymph node metastases before treatment. Of these 49 patients, nine (18.4%) presented with sentinel lymph node metastasis, which occurred after treatment in three (6.1%) of them (false-negative). Among the 107 patients who did not undergo lymph node biopsy, 12 (11.2%) developed post-treatment metastases. The metastasis-free and disease-specific survival rates were not significantly different in those who did or did not undergo sentinel lymph node biopsy. Patients with clinical lymph node metastases had a higher risk compared with those without. Patients with T2-T4 tumors had a higher risk compared with those with T1 tumors. When selecting for those with T2 tumors or greater, the same lack of relationship was observed. In conclusion, in this small retrospective cohort, in patients with cutaneous squamous cell carcinoma, there were no significant differences in metastasis-free and disease-specific survival rates between those who did or did not undergo sentinel lymph node biopsy, regardless of T staging.

show abstract

Cutaneous squamous cell carcinoma and related entities: Epidemiology, clinical and histological features, and basic science overview

Cited by 30 publications

References 77 publications

MicroRNA‑186 promotes cell proliferation and inhibits cell apoptosis in cutaneous squamous cell carcinoma by targeting RETREG1

MicroRNA‑186 promotes cell proliferation and inhibits cell apoptosis in cutaneous squamous cell carcinoma by targeting RETREG1

Review of high‐risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology

Availability of sentinel lymph node biopsy for cutaneous squamous cell carcinoma

Contact Info

Product

Resources

About